With just months remaining in the Oregon Health & Science University (OHSU) Pathfinder 2 study for early detection of cancer, the Knight Cancer Institute brings
With just months remaining in the Oregon Health & Science University (OHSU) Pathfinder 2 study for early detection of cancer, the Knight Cancer Institute brings
Shivaani Kummar, MBBS, FACP, discusses the mechanism of action of the TP53-directed agent rezatapopt and efficacy data with this agent in solid tumors.